SABCS 2023 | Advancing personalized breast cancer treatment: insights from ECOG-ACRIN E4112 and ADAPTcycle trials

Rick Baehner, MD, from Exact Sciences, discusses the significance of ECOG-ACRIN E4112 (NCT02352883) and ADAPTcycle (NCT04055493) trials, highlighting their role in individualizing breast cancer treatment decisions. These trials emphasize the incorporation of clinical, pathologic, and molecular factors, such as DCI and recurrence scores, alongside newer attributes like ki67 responsiveness. This comprehensive approach allows for tailored treatment decisions, enabling the reduction of cytotoxic chemotherapy and radiotherapy, especially in cases of ductal carcinoma in situ. The ongoing advancements, including the use of circulating tumor DNA (ctDNA) and molecular residual disease assessment, promise to further refine risk assessments and individualize patient treatment decisions. This interview occurred at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.